Lifecore Agrees To $663.7 Million Buyout Deal With Webster Equity Partners; Stock Up
Lifecore Biomedical (LFCR) agreed to a $663.7M buyout by Webster Equity Partners at $6.28 per share, a 49.5% premium. Shareholders may receive additional payments if performance milestones are met. The deal, approved by the board, is expected to close by Q4 2026. LFCR shares rose 56.79% to $6.59.
How this was made
The 30-second read
Why it matters
The premium and cash consideration immediately lift the stock, while the pending regulatory and shareholder approvals introduce near‑term uncertainty.
Market read
A material M&A deal that directly moves LFCR stock; traders should consider buying on the premium or shorting if they doubt deal completion.
What to watch
Potential regulatory hurdles and the go‑shop period could introduce deal risk; post‑close integration execution remains uncertain.
Background
The announcement follows Lifecore's recent share price volatility and reflects private‑equity interest in expanding CDMO capabilities.
Ticker impact
Lifecore Biomedical announced a definitive acquisition by Webster Equity Partners at $6.28 per share cash plus contingent value rights, a 49.5% premium to the prior close.
upward pressure as investors price in the premium and cash consideration
The transaction is a fresh, material M&A announcement with a sizable cash component and a potential additional $160 M contingent payout, causing a 56% intraday rise.
Market effects
Consolidation in the CDMO/pharma contract manufacturing sector may spur valuation reassessments for peers.
Mid‑west biotech exposure gains as a Minnesota‑based firm is taken private.
Limited to biotech and private‑equity investors; no broad market effect.
Counterpoint
If the contingent value rights fail to materialize, the effective purchase price could be lower, leaving upside limited.
Key entities
- CompanyLifecore Biomedical, Inc.
US‑listed CDMO targeted for acquisition.
- Private Equity FirmWebster Equity Partners
Acquirer providing cash and financing for the deal.
